According to recent research by Decision Resources, physicians continue to prescribe GlaxoSmithKline Avandia over newer diabetic drugs Byetta (Amlin/Eli Lilly) and Januvia (Merck.)
Safety warnings have been applied to Avandia on account of a controversial journal report that linked the drug to heart disease and death. The findings were part of a report by Decision Resources entitled: “GLP-1 Analogues vs. DPP-IV Inhibitors – Which Class Will Change the Face of the Diabetes Market?”
To glean the data, DR asked physicians to outline their drug treatment programs. The report concluded that only 15 per cent of patients would switch, and that: “clinicians are more like to switch patients to Takeda’s Actos than to Byetta or Januvia.”
The survey investigated the views of 21 managed care pharmacy directors, 72 endocrinologists, and 73 primary care physicians.

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Public Health England considers low carb approach for type 2 diabetes

The low carb approach is being considered by the government to be…

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…

Conversation about doctors’ appointments occurring virtually rumbles on

More than half of GP appointments are still being delivered remotely in…